Re­gen­eron of­fers a pos­i­tive look at the first cut of its Covid-19 an­ti­body cock­tail — but just how well does it pro­tect a vul­ner­a­ble group?

On the heels of a dis­ap­point­ing per­for­mance by Eli Lil­ly’s an­ti­body tar­get­ing the coro­n­avirus, Re­gen­eron is now step­ping up with ev­i­dence that its an­ti­body cock­tail — at the high dose — has a sig­nif­i­cant im­pact on slash­ing vi­ral load in pa­tients most at risk of a dan­ger­ous re­ac­tion. And they plan to hus­tle the first cut of the da­ta to reg­u­la­tors, who have al­ready shown an ea­ger­ness in get­ting drugs out to com­bat Covid-19 as quick­ly as pos­si­ble.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN